2017 awards WINNERS & FINALISTS

2017 awards WINNER & FINALISTS 

#BMGalaDinner

 


 

uk life science SPIN-OUT OF THE YEAR (<1 year FROM SPIN-OUT)

Open to privately owned Life Science companies and their Tech Transfer Office

Hosted by:     JA Kemp.jpg

Achilles Therapeutics, UCL, CRT and the Francis Crick Institute
Apollo Therapeutics, Imperial Innovations, UCLB and Cambridge Enterprise
Cardian, Imperial Innovations
Circadian Therapeutics, Oxford University Innovation
RUNNER-UP - GammaDelta Therapeutics, KCL / Francis Crick Institute and CRT
Keapstone Therapeutics, University of Sheffield
WINNER - Microbiotica, Wellcome Trust Sanger Institute
SuperX

 

UK LIFE SCIENCE YOUNG COMPANY OF THE YEAR (1-3 YEARS OLD)

Open to privately owned Life Science companies that are between 1 and 3 years on from incorporation.

Hosted by:Clinigen-3.png

Autolus
WINNER - Artios Pharma
Auspherix
Benevolent AI
Freeline Therapeutics
NightstaRx
Orchard Therapeutics
RUNNER-UP - Tusk Therapeutics

 

UK PRIVATE LIFE SCIENCE GROWTH COMPANY OF THE YEAR (>3 YEARS OLD) 

Open to privately owned Life Science companies that are greater than 3 years on from incorporation.

WINNER - Bicycle Therapeutics
Cell Medica
Crescendo Biologics
RUNNER-UP - F-Star
Immunocore
Kymab
MISSION Therapeutics
PsiOxus Therapeutics

 

Uk life science DEAL OF THE YEAR

Open to either private or public life science companies, their Pharma partners and their Advisors.

Abzena and OBI Pharma - $300m licensing deal
RUNNER-UP - Bicycle Therapeutics and AstraZeneca - $1bn peptide collaboration
Crescendo Biologics - Takeda $790m cancer collaboration
WINNER - F-Star and Merck – €1bn immuno-oncology collaboration
GammaDelta Therapeutics and Takeda - $100m investment / acquisition option
PsiOxus Therapeutics and BMS - $936m deal
Summit Therapeutics and Sarepta - $584m+ DMD pipeline EU license pact
Vectura and Skyepharma merger

 

UK PRIVATE finance raise of THE YEAR (£25m)

Open to privately owned Life Science companies and their lead investors.

WINNER - Artios Pharma - £25m, Series A, SVLS, Touchstone Innovations, Arix Bioscience, Merck Ventures, Abbvie, CRT Pioneer Fund
Achilles Therapeutics - £13.2m, Seed Financing, Syncona, CRT Pioneer Fund and the UCL Technology Fund
ApcinteX - £14m Series A, Medicxi, Touchstone Innovations
RUNNER-UP - Congenica - £8m, Series B, CIC, Amadeus Capital Partners, Parkwalk Advisors
NeRRe Therapeutics - £23m, Series B - Advent Life Sciences, Fountain Healthcare Partners, Orbimed, Forbion
Oxular - £15.5m, Series A, V-Bio Ventures,Touchstone Innovations, Consort Medical, NeoMed and Hovione Scientia
Pulmocide - £24m, Series B, SR-One, SV Life Sciences, Touchstone Innovations, JJVC, F-Prime Capital

 

UK PRIVATE FINANCE RAISE OF THE YEAR (>£25M)

Open to privately owned Life Science companies and their lead investors.

Atlas Genetics - £28.3m, Series D, Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners, YFM Equity Partners and Wondfo Biotech 
RUNNER-UP - Bicycle Therapeutics - £40m, Series B, Vertex Ventures, Cambridge Innovation Capital, Longwood Fund. Novartis VG, SR-One, SVLS and Atlas Venture
WINNER - Carrick Therapeutics - £74m, Series A, ARCH Venture Partners and Woodford Investment Management, Cambridge Enterprise, Evotec AG, Google Ventures, Lightstone Venture and Cambridge Innovation Capital
Cell Medica - £60m, Series C, Touchstone Innovations, Invesco Perpetual and Woodford Investment Management
F2G - £46.5m, Series E, Sectoral Asset Management, Novo A/S, Aisling Capital, Advent Life Sciences, Novartis VF, Sunstone, Merifin Capital
Kymab - £78m, Series C,ORI Healthcare Fund
Oxford Nanopore - £100m, Venture Financing, GT Healthcare Healthcare Partners, Woodford Investment Management and IP Group Plc.

 

UK LIFE SCIENCE IPO OF THE YEAR 

Open to newly publicly listed Life Science companies and their Advisors.

RUNNER-UP - ConvaTec - £1,465m raise, issue price £2.25p (CTEC:LSE)
CREO Medical - £20m raise, issue price £0.76p (CREO:LSE)
Medica Group - £121m raise, issue price £1.35p (MGP:LSE)
Oxford Biodynamics - £20m raise, issue price £1.58p (OBD:LSE)
SkinBio Therapeutics - £4.5m raise, issue price £0.09p (SBTX:LSE)
WINNER - Verona Pharma - $78m raise, issue price $13.50 (VRNA:US NASDAQ)
Widecells - £2m raise, issue price £0.113p (WDC:LSE)

 

UK PUBLIC FINANCE RAISE OF THE YEAR 

Open to publicly listed Life Science companies and their Advisors. Raise must be non-IPO.

Abzena - £25m raised to expand further its service offering, capacity and capabilities
C4X Discovery - £7m raised to continue to build its existing pipeline of five preclinical assets
Genedrive - £6.5m raised to broaden the portfolio of its Genedrive tests, developed to fight infectious diseases
Midatech Pharma - £16m raised to expand and advance its oncology-focused development pipeline
WINNER - Oxford BioMedica - £10m raised to fund progress on its discovery and pre-clinical projects
Scancell Holdings - £5m raised to fund clinical work on its pipeline of cancer immune-therapies
RUNNER-UP - Verona Pharma - £44.7m raised to fund RPL554 through a phase 2b clinical trial in chronic obstructive pulmonary disease (COPD) patients and additional phase 2 studies in both COPD and cystic fibrosis

 

UK PUBLIC LIFE SCIENCE COMPANY OF THE YEAR 

Open to pubicly owned Life Science companies only. 

Hosted by:      CMS Cameron Mckenna .png

Abzena
Adaptimmune
RUNNER-UP - Astrazeneca
Clinigen
WINNER - Horizon Discovery
Oxford BioMedica
Shield Therapeutics
Summit Therapeutics

 

life science communication strategy of THE YEAR 

Open to private or public life science companies and their PR / IR and Strategic Communications Firm.

Hosted by:     EQS-Logo.jpg

RUNNER-UP - Astex Pharmaceuticals and Instinctif
Evgen Pharma and Buchanan
F2G and Hume Brophy
Heptares Therapeutics and Citigate Dewe Rogerson
WINNER - Horizon Discovery and Consilium Strategic Communications
Optibiotix and Walbrook PR
Verona Pharma and FTI Consulting

 

uk PRIVATE AND PUBLIC life science ceo of THE YEAR 

Open to CEOs from both privately and publicly owned Life Science companies.

PRIVATE

David Chiswell, Kymab
John Beadle, PsiOxus Therapeutics
WINNER - John Haurum, F-Star
Christian Itin, Autolus
RUNNER-UP - Kevin Lee, Bicycle Therapeutics
Anker Lundemose, MISSION Therapeutics
Peter Pack, Crescendo Biologics
Gordon Sanghera, Oxford Nanopore

 

PUBLIC

John Burt, Abzena
Shaun Chilton, Clinigen
John Dawson, Oxford BioMedica
WINNER - Darrin Disley, Horizon Discovery
Clive Dix, C4X Discovery
Glyn Edwards, Summit Therapeutics
RUNNER-UP - Dame Louise Makin, BTG
James Ward-Lilley, Vectura